Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Trastuzumab Pamirtecan · DB-1303, BNT-323

Antibody-drug conjugate · Cytotoxic, directed at HER2 (ERBB2) and DNA topoisomerase I (TOP1) · developed by BioNTech

Phase 3 Most advanced trial
BNTX Developer
3 Registered trials

What is Trastuzumab Pamirtecan?

Trastuzumab pamirtecan is an antibody-drug conjugate in which the anti-HER2 antibody trastuzumab is linked by a cleavable linker to the topoisomerase I inhibitor P1003. After binding HER2 on tumor cells and being internalized, the payload is released and inhibits DNA topoisomerase 1, causing cell cycle arrest and apoptosis. It is studied in breast cancer and endometrial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
DB-1303, BNT-323
Drug type
Antibody-drug conjugate
Targets
HER2 (ERBB2), DNA topoisomerase I (TOP1)
Mechanism
Cytotoxic, directed at HER2 (ERBB2) and DNA topoisomerase I (TOP1)
Pathways
DNA replication inhibition, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
BioNTech SE (BNTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
WPL7XBK5KU

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06340568 Phase 3 Endometrial Cancer Recruiting BNTX
NCT06018337 Phase 3 Metastatic Breast Cancer Active not recruiting BNTX
NCT06827236 Phase 1/2 Locally Advanced Breast Cancer Recruiting BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial CancerLocally Advanced Breast CancerMetastatic Breast CancerUnresectable Breast Carcinoma

Other drugs acting on ERBB2 / TOP1

More from BioNTech

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the BNTX page.

Follow BNTX, the company behind Trastuzumab Pamirtecan

See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BNTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.